ライフサイエンスコーパス: C5a receptor

1 icular, in ligand-mediated activation of the C5a receptor.

2 the seven transmembrane helices of the human C5a receptor.

3 he seven transmembrane segments of the human C5a receptor.

4 t couples in neutrophils is reported to be a C5a receptor.

5 kely G protein linked, but distinct from the C5a receptor.

6 ue to inhibition of C5a interaction with the C5a receptor.

7 er in mice treated with an antagonist of the C5a receptor.

8 the order CXCR2 > CXCR1 > formyl peptide or C5a receptors.

9 onstitutively express functionally competent C5a receptors.

10 man and murine brains constitutively express C5a receptors.

11 human neuroblastoma cells express functional C5a receptors.

12 in CMs, which required availability of both C5a receptors.

13 e show that activation of complement C5a and C5a receptor 1 (C5aR1) controls GC accumulation and the

14 activation is implicated in AKI, the role of C5a receptor 1 (C5aR1) in kidney tubular cells is unclea

15 ent anaphylatoxin C5a-mediated activation of C5a receptor 1 (C5aR1) on platelets as a negative regula

16 FcepsilonR1-mediated MC functions including C5a receptor 1 (C5aR1) regulation.

17 gnals through the G-protein-coupled receptor C5a receptor 1 (C5aR1) to induce the chemotaxis of prima

18 tracellular C5 activation and stimulation of C5a receptor 1 (C5aR1), which is negatively regulated by

19 receptor [C3aR] and complement anaphylatoxin C5a receptor 1 [C5aR1]) on human umbilical vascular endo

20 , whereupon it interacts with the complement C5a receptor 1 expressed on tumor infiltrating myeloid-d

21 rmostable mutations of the complement factor C5a receptor 1 retrieved 36% of the thermostable mutants

22 o the premetastatic lungs through complement C5a receptor 1 signaling.

23 Blockade of C5a receptor 1 synergized with antiangiogenic Listeria m

24 educing RPS19 in tumor cells or blocking the C5a receptor 1-RPS19 interaction decreases RPS19-mediate

25 ent, as did impaired AM phagocytosis through C5a receptor 1/Fc-gamma receptor I inhibition or by stea

26 The two ligands jointly trigger EC C5a receptor-1 (C5ar1) and PAR4 signaling, which togethe

27 tacyclin (PGI2) production via activation of C5a receptor 2 (C5aR2).

28 t and third extracellular loops of the human C5a receptor, a GPCR that binds a 74-amino acid peptide

29 ), can act as agonists or antagonists to the C5a receptor, a member of the GPCR family.

30 ttle energy transfer is observed between the C5a receptor and a co-expressed yeast pheromone receptor

31 5a can bind to two distinct receptors (i.e., C5a receptor and C5a receptor-like 2 [C5L2]).

32 with cDNAs encoding the complement component C5a receptor and PLC beta2 but not in cells transfected

33 sepsis by using antibody-induced blockade of C5a receptors and knockout mice.

34 L, signalling pathways downstream of C3a and C5a receptors and membrane C5b-9 assembly, and the preve

35 production of MIP-2 and KC by PTECs, whereas C5a receptor antagonism and prevention of membrane attac

36 d opsonization >2-fold, and compstatin and a C5a receptor antagonist (C5aRa) impaired granulocyte act

37 were alleviated by pretreating cells with a C5a receptor antagonist (C5aRant) or a C5a antibody.

38 Here, oral delivery of a cyclic hexapeptide C5a receptor antagonist (PMX205) for 2-3 mo resulted in

39 Avacopan, an oral C5a receptor antagonist, was approved as an adjunctive t

40 We investigated the role of C5a-receptor antagonist (C5aRA) solely and in combinatio

41 In mice, loss of C5 or injection of a C5a-receptor antagonist significantly reduced the level

42 C5aRAM and C5aRAD are novel, potent C5a receptor antagonists devoid of agonist or proinflamm

43 Novel recombinant human C5a receptor antagonists were discovered through modific

44 -deficient mice and mice given injections of C5a-receptor antagonists developed significantly less pa

45 osition in mice deficient in C3a receptor or C5a receptor, as well as in wild-type mice depleted of h

46 nd synaptic loss, elevation of anaphylatoxin C5a receptor, astrocytic-C3, and microglial-TLR4 express

47 increase is prevented by blockade of the C5a-C5a receptor axis.

48 Complement C3a and C5a receptor blockade in this system suppressed basophil

49 Neuronal C5a receptors bound C5a-coated fluorescent microspheres,

50 ent human serum resulted in up-regulation of C5a receptor, but not C3a receptor.

51 TGF-beta), and whereas TGF-beta1 induced C3a/C5a receptor (C3aR/C5aR) expression, pharmacologic C3aR/

52 The functions of glial-cell C3a and C5a receptors (C3aR and C5aR) appear to be similar to im

53 roid was assayed for the presence of C3a and C5a receptors (C3aR and C5aR) using RT-PCR and immunohis

54 nt studies, we showed that autocrine C3a and C5a receptor (C3ar1 and C5ar1) G protein-coupled recepto

55 ombination (CSR) depend on autocrine C3a and C5a receptor (C3ar1/C5ar1) signaling in B2 cells.

56 his article, we show that suppressed C3a and C5a receptor (C3ar1/C5ar1) signaling in murine Tregs pla

57 sponses, requires autocrine C3a receptor and C5a receptor (C3ar1/C5ar1) signaling.

58 activation and neutrophil-expressed C3a and C5a receptors (C3aR1/C5aR1) that promote BAFF-dependent

59 HNFAG09, with 37% nucleotide identity to the C5a receptor (C5a-R, CD88) was identified.

60 autoantibody-induced arthritis requires the C5a receptor C5aR and FcgammaRs, but the simultaneous ne

61 the e2 loop with a smaller e2 loop from the C5a receptor (C5aR) abolished binding of 125I-C3a and C3

62 Furthermore, blockade of the C5a receptor (C5aR) abrogated the ability of hepatocytes

63 biting signaling of the complement component C5a receptor (C5aR) altered the composition and diversit

64 irst evidence that human T cells express the C5a receptor (C5aR) and are chemotactic to C5a.

65 signals transmitted through T cell-expressed C5a receptor (C5aR) and C3a receptor (C3aR) to activatio

66 functions through two identified receptors, C5a receptor (C5aR) and C5L2.

67 Little is known about the role of the C5a receptor (C5aR) and its presence in different organs

68 onocytic cell line U937 transfected with the C5a receptor (C5aR) and loaded with a fluorescent intrac

69 Complement C5a receptor (C5aR) antagonism in C3aR(-/-) mice also re

70 Small molecule C5a receptor (C5aR) antagonist development is hampered b

71 C3a receptor (C3aR) or C5a receptor (C5aR) antagonists were administered to mic

72 the terminal complement component C5 and the C5a receptor (C5aR) are upregulated in spinal microglia

73 nt, these changes being complement (C5a) and C5a receptor (C5aR) dependent.

74 been shown to be an important inducer of the C5a receptor (C5aR) during sepsis.

75 ast cancer that the complement anaphylatoxin C5a receptor (C5aR) facilitates metastasis by suppressin

76 The complement anaphylatoxin C5a receptor (C5aR) has been implicated in inflammatory

77 We have demonstrated that the C5a receptor (C5aR) has crucial roles in regeneration an

78 d the role of the active fragment complement C5a receptor (C5aR) in dental nerve regeneration in rega

79 prevented by the deficiency of either C3 or C5a receptor (C5aR) in the APC, demonstrating a link bet

80 We found that mice deficient in MCs or the C5a receptor (C5aR) injected with pathogenic anti-BP180

81 Because the expression of the C5a receptor (C5aR) is significantly increased in brain

82 there are some suggestions that C5a and the C5a receptor (C5aR) might be directly linked to apoptosi

83 naphylatoxin C5a results in reduction of the C5a receptor (C5aR) on neutrophils.

84 a (tC5aF) and flow cytometry to identify the C5a receptor (C5aR) on trout leukocytes.

85 lacking the chemotactic or adhesion receptor C5a receptor (C5aR) or CD11a/lymphocyte function-associa

86 e show that pharmacological targeting of the C5a receptor (C5aR) or the bradykinin B2 receptor (B2R)

87 that local pharmacological targeting of the C5a receptor (C5aR) prior to initial allergen sensitizat

88 8(+) T cells lacking C3a receptor (C3aR) and C5a receptor (C5aR) proliferate weakly to allogeneic DCs

89 ostaining data demonstrate that blocking the C5a receptor (C5aR) reduced BDNF production in DPSCs, wh

90 ells deficient in C3a receptor (C3aR) and/or C5a receptor (C5aR) responded weakly in allogeneic hosts

91 Complement fragment 5a (C5a)-C5a receptor (C5aR) signaling plays an essential role in

92 Both mRNA and protein for the C5a receptor (C5aR) were constitutively expressed on car

93 in untreated fibroblast cultures express the C5a receptor (C5aR), here we show that all dental pulp f

94 f a cyclic peptide antagonist (C5aRa) to the C5a receptor (C5aR), the binding of murine 125I-C5a to m

95 C5a receptor (C5aR)-targeting of C3aR-deficient mice dur

96 ciated with increased levels of mRNA for the C5a receptor (C5aR).

97 protein-coupled receptors, C3a receptor and C5a receptor (C5aR).

98 ffects of C5a are mediated by its binding to C5a receptor (C5aR, CD88).

99 The NH(2)-terminal domain of the C5a receptor (C5aR/CD88) contributes substantially to it

100 pressed both the C3a receptor (C3aR) and the C5a receptor (C5aR; CD88) on the cell surface.

101 own that mice deficient either in complement C5a receptor (C5aR; CD88) or TLR2 are highly and similar

102 ibody raised against residues 9 to 29 of the C5a receptor (C5aR; CD88), we demonstrate that noncystei

103 cule that mediates its effects by binding to C5a receptor (C5aR; CD88).

104 ins C3a and C5a (ie, C3a receptor [C3aR] and C5a receptor [C5aR]), and C3a and C5a are generated duri

105 The biological significance of C5a receptor [(C5aR)2/C5L2], a seven-transmembrane recep

106 The function of the C5a receptors, C5ar (encoded by C5ar) and C5l2 (encoded

107 d the potential of peritoneal TLR2, TLR4 and C5a receptors, C5aR and C5L2, as therapeutic targets in

108 Here, the role of the complement C5a receptor C5aR1 was examined in the progression and m

109 Absence of either C5a receptor (C5aR1 or C5aR2) diminished development of

110 Here, we show that silencing the C5a receptor (C5aR1) in Schwann cells blocks the C5a-ind

111 eted mice and in mice treated with PMX205, a C5a receptor (C5aR1) inhibitor.

112 C5a upregulation and was markedly reduced by C5a receptor (C5aR1) knock-out or treatment with the C5a

113 We previously showed that C5a receptor (C5aR1) signaling on T cells activates Teff

114 We demonstrate a crucial role of the C5a receptor, C5aR1, in the development of inflammatory

115 C5a acts through two C5a receptors, C5aR1 (C5aR, CD88) and C5aR2 (C5L2, GPR77

116 Two C5a receptors, C5aR1 (C5aR, CD88) and C5aR2 (C5L2, GPR77

117 in left ventricular (LV) CMs, requiring both C5a receptors, C5aR1 and -2.

118 ulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple sign

119 However, the role of the alternative C5a receptor, C5aR2, which is commonly thought to be mor

120 e have analyzed the expression of the second C5a receptor C5L2, the putative "default" or nonsignalin

121 A second C5a receptor, C5L2, has also been cloned but has receive

122 ptor C5aR, but was independent of the second C5a receptor, C5L2.

123 ively investigated how C5a signaling through C5a receptors can modulate diverse PRR-mediated cytokine

124 Phis and in the second by treatment with the C5a receptor (CD88) agonist EP67, which invokes MPhi pro

125 ated the regulated expression of the C3a and C5a receptors (complement anaphylatoxin C3a receptor [C3

126 Pharmacological blockade of the C5a receptor considerably impaired tumor growth to a deg

127 ed with pertussis toxin, suggesting that the C5a receptor couples to both Galpha15 and Galphai in viv

128 C5a receptor deficiency, which also lessens myeloid-deri

129 In contrast, C5a receptor deficient mice, which bear C5L2 alone, do n

130 cordingly, we found enhanced Th1 immunity in C5a receptor-deficient mice, something that conferred pr

131 These C5a-receptor-deficient mice challenged with sublethal in

132 al reactive oxygen species (ROS), which were C5a-receptor dependent.

133 In contrast, the interleukin-8 and C5a receptors did not couple to Galphaq in either COS-7

134 eptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations wit

135 gulator of cell polarity, with inhibition of C5a receptors during embryogenesis leading to abnormal b

136 sonance energy transfer experiments on human C5a receptors expressed in the lower eukaryote Saccharom

137 The oligomerization of C5a receptors expressed in yeast displays characteristic

138 disulfide-trapping experiments to show that C5a receptors, expressed in mammalian cells, reside in m

139 IL-17 is produced by complement C5a-receptor-expressing T-cells.

140 We report that genetic ablation of C5a receptor expression completely protects mice from ar

141 Based on these observations, we propose that C5a receptors form higher order oligomers (i.e. tetramer

142 To begin to address how C5a receptors form oligomers, we now use fluorescence re

143 nists have been developed to interrogate the C5a receptor function but none show selectivity for C5aR

144 a (C5a) for the knockdown of seven proteins (C5a receptor; G-beta-2; G-alpha,i-2,3; regulator of G-pr

145 N-terminal segment with that from the human C5a receptor had minimal effect on C3a binding, substitu

146 We conclude that the C5a receptor has a non-redundant function, and is requir

147 is a pore-forming toxin targeting the human C5a receptor (hC5aR), enabling this pathogen to battle t

148 co-transfected with both G alpha 16 and the C5a receptor, iC5b67 could neither activate phospholipas

149 the anaphylotoxin receptors C3a receptor and C5a receptor in nonimmune respiratory cells can prevent

150 Expression of the C5a receptor in the central nervous system has been demo

151 lar levels of energy transfer between tagged C5a receptors in endoplasmic reticulum compared with pla

152 Overexpression of various mammalian C5a receptors in HEK cells confirms that cytotoxicity to

153 ct surfaces, we demonstrate cross-linking of C5a receptors in membranes prepared from both human neut

154 f murine sepsis, we investigated the role of C5a receptors in septic lymphopenia.

155 w that mice deficient in the chemoattractant C5a receptor, in comparison to their wild-type littermat

156 d macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven throug

157 d macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven throug

158 Similarly, antagonists of the C3a or C5a receptors inhibited tumor growth.

159 plement heat-inactivation, C5 depletion, and C5a receptor inhibition suppressed the priming effect of

160 In conclusion, C5a receptor inhibition with avacopan was effective in r

161 The C5a receptor inhibitor avacopan is being studied for the

162 (CCX168), an orally administered, selective C5a receptor inhibitor, could replace oral glucocorticoi

163 we show that Ab's or peptides that block C5a-C5a receptor interactions prevent pregnancy complication

164 The Galpha(i)-protein-coupled C5a receptor is a critical regulator of IgG FcR function

165 rprisingly the carboxyl-terminal tail of the C5a receptor is the most important specificity determina

166 Since the complement receptor C5a receptor-like 2 (C5L2) is expressed by different ste

167 that is, complement receptor C5a (C5aR) and C5a receptor-like 2 (C5L2), in sepsis have been demonstr

168 s through its two receptors, C5aR (CD88) and C5a receptor-like 2 (C5L2).

169 o distinct receptors (i.e., C5a receptor and C5a receptor-like 2 [C5L2]).

170 ic DAF overexpression or deletion of C3a and C5a receptors limited the activation of mechanistic targ

171 neither activate phospholipase C nor inhibit C5a receptor-mediated activation of phospholipase C. iC5

172 nd Gbeta subunits contributing to complement C5a receptor-mediated chemotaxis.

173 n the premetastatic lungs through complement C5a receptor-mediated proliferation but not through recr

174 bit distinct inhibitory effects on fMLP (and C5a) receptor-mediated superoxide production, but have n

175 The absence of either C5a receptor mitigated sepsis-induced reductions in the

176 ression is almost completely absent, whereas C5a receptor mRNA and protein expression is maintained.

177 collection of 133 functional mutants of the C5a receptor obtained in a mutagenesis screen targeting

178 receptor (encoded by STE2), indicating that C5a receptor oligomerization is both receptor-specific a

179 lian accessory proteins are not required for C5a receptor oligomerization.

180 ntine receptor that is co-expressed with the C5a receptor on many cells including polymorphonuclear n

181 gineered near a proposed binding site in the C5a receptor on transmembrane helices III and VI can sel

182 ic TNF-alpha in the absence of C3a receptor, C5a receptor, or hepatic macrophages.

183 shown that antibody-induced blockade of C5a, C5a receptors, or IL-17A greatly reduced the harmful out

184 ng of the C5a component of complement to the C5a receptor plays an important role in CD8(+) T cell re

185 histones appearing in septic plasma required C5a receptors, polymorphonuclear leukocytes (PMNs), and

186 lates the Gi proteins known to couple to the C5a receptor, produced minimal inhibition of C5a-induced

187 Blockade of the C5a receptor rendered human monocytes unable to produce

188 te that simultaneous blockade of the C3a and C5a receptors represents a promising neuroprotective str

189 conducted to address the functional role of C5a receptors revealed that C5a triggered rapid activati

190 Africans and linked to a polymorphism of the C5a receptor (rs11880097 T/G), the cellular target of th

191 Interception of C5a receptor signaling resulted in suppression of IL-6/T

192 of the carboxyl-terminal tail did not impair C5a receptor signaling.

193 phagocytosis could be prevented by blocking C5a receptor signaling.

194 mbrane attack complex and activated C3a- and C5a-receptor signals required for positive selection.

195 In particular, blockade of C5a receptor significantly reduced myeloid-derived suppr

196 f IL-6/TNFalpha induction and lack of C3 and C5a receptor stimulation attenuated nuclear factor-kappa

197 C5a receptors tagged with variants of the green fluoresc

198 s showed significant expression of the trout C5a receptor (TC5aR) message in PBLs and kidney.

199 idues on the intracellular face of the human C5a receptor that are involved in G protein activation,

200 Functional roles for both C5a receptors, that is, complement receptor C5a (C5aR) a

201 tructural model of the inactive state of the C5a receptor, the preserved residues reside on one half

202 V, VI, and VII of the human chemoattractant C5a receptor to random saturation mutagenesis.

203 trophils and U937 cells transfected with the C5a receptor (U937-C5aR cells) and comparing chemotaxis

204 Strong cell surface expression of C5a receptors was detected on PMN, whereas NK cells comp

205 Engagement of C3a and C5a receptors was ruled out.

206 , internalization of the FPR, as well as the C5a receptor, was demonstrated to be independent of the

207 We found that the complement effect required C5a receptor, was evident at physiologically relevant le

208 might be involved in the oligomerization of C5a receptors, we constructed receptors with individual

209 or B, C3 and properdin, and C3a receptor and C5a receptor were detected in grade 3 versus grade 0 or

210 erefore different from that reported for the C5a receptor, which is required for the initial inductio

211 C5a receptors with a cysteine in the first intracellular

212 opy to measure the kinetics of movement of a C5a receptor-yellow fluorescent protein fusion in living